DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the 'DKFZ Sarcoma Classifier'.


Journal

The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534

Informations de publication

Date de publication:
07 2021
Historique:
revised: 26 02 2021
received: 15 01 2021
accepted: 18 03 2021
pubmed: 6 5 2021
medline: 22 1 2022
entrez: 5 5 2021
Statut: ppublish

Résumé

Diagnosing bone and soft tissue neoplasms remains challenging because of the large number of subtypes, many of which lack diagnostic biomarkers. DNA methylation profiles have proven to be a reliable basis for the classification of brain tumours and, following this success, a DNA methylation-based sarcoma classification tool from the Deutsches Krebsforschungszentrum (DKFZ) in Heidelberg has been developed. In this study, we assessed the performance of their classifier on DNA methylation profiles of an independent data set of 986 bone and soft tissue tumours and controls. We found that the 'DKFZ Sarcoma Classifier' was able to produce a diagnostic prediction for 55% of the 986 samples, with 83% of these predictions concordant with the histological diagnosis. On limiting the validation to the 820 cases with histological diagnoses for which the DKFZ Classifier was trained, 61% of cases received a prediction, and the histological diagnosis was concordant with the predicted methylation class in 88% of these cases, findings comparable to those reported in the DKFZ Classifier paper. The classifier performed best when diagnosing mesenchymal chondrosarcomas (CHSs, 88% sensitivity), chordomas (85% sensitivity), and fibrous dysplasia (83% sensitivity). Amongst the subtypes least often classified correctly were clear cell CHSs (14% sensitivity), malignant peripheral nerve sheath tumours (27% sensitivity), and pleomorphic liposarcomas (29% sensitivity). The classifier predictions resulted in revision of the histological diagnosis in six of our cases. We observed that, although a higher tumour purity resulted in a greater likelihood of a prediction being made, it did not correlate with classifier accuracy. Our results show that the DKFZ Classifier represents a powerful research tool for exploring the pathogenesis of sarcoma; with refinement, it has the potential to be a valuable diagnostic tool.

Identifiants

pubmed: 33949149
doi: 10.1002/cjp2.215
pmc: PMC8185366
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

350-360

Subventions

Organisme : Cancer Research UK
ID : 18387
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.

Références

Nat Commun. 2018 Jul 17;9(1):2765
pubmed: 30018380
Biochim Biophys Acta. 2013 Nov;1829(11):1161-74
pubmed: 23938249
Acta Neuropathol. 2016 Jun;131(6):877-87
pubmed: 26857854
Int J Cancer. 2012 Aug 15;131(4):E508-17
pubmed: 21913189
Nat Commun. 2021 Jan 21;12(1):498
pubmed: 33479225
Nat Commun. 2013;4:2166
pubmed: 23863747
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
BMJ. 2019 Mar 12;364:l886
pubmed: 30862612
J Pathol Clin Res. 2020 Apr;6(2):113-123
pubmed: 31916407
Neurooncol Adv. 2019 Nov 28;2(Suppl 1):i50-i61
pubmed: 32642732
Am J Surg Pathol. 2016 Apr;40(4):479-89
pubmed: 26645727
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
Cancer Res. 2019 Jan 1;79(1):7-20
pubmed: 30389703
Cancer Cell. 2019 Mar 18;35(3):441-456.e8
pubmed: 30889380
J Pathol Clin Res. 2020 Oct;6(4):297-307
pubmed: 32573957
Nat Genet. 2012 Mar 04;44(4):461-6
pubmed: 22387997
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Lancet Child Adolesc Health. 2020 Feb;4(2):121-130
pubmed: 31786093
Mod Pathol. 2007 Apr;20(4):482-96
pubmed: 17334349
Mod Pathol. 2016 Jun;29(6):582-90
pubmed: 26990975
Neuropathol Appl Neurobiol. 2020 Aug;46(5):478-492
pubmed: 32072658
Nat Commun. 2017 Jun 23;8:15936
pubmed: 28643781
Genes (Basel). 2020 Apr 02;11(4):
pubmed: 32252413
Oncotarget. 2015 Dec 15;6(40):42429-44
pubmed: 26643872
Pac Symp Biocomput. 2018;23:204-215
pubmed: 29218882
J Pathol. 2020 Oct;252(2):151-164
pubmed: 32666581
Cancer Genet Cytogenet. 2009 Nov;195(1):1-11
pubmed: 19837261
BMC Bioinformatics. 2019 Aug 16;20(1):428
pubmed: 31419933
J Pathol. 2020 Dec;252(4):433-440
pubmed: 32866294

Auteurs

Iben Lyskjaer (I)

Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
Medical Genomics Research Group, University College London, UCL Cancer Institute, London, UK.

Solange De Noon (S)

Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Roberto Tirabosco (R)

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Ana Maia Rocha (AM)

Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Daniel Lindsay (D)

Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Fernanda Amary (F)

Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Hongtao Ye (H)

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Daniel Schrimpf (D)

Department of Neuropathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Damian Stichel (D)

Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Martin Sill (M)

Hopp-Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Christian Koelsche (C)

Department of Neuropathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of General Pathology, University of Heidelberg, Heidelberg, Germany.

Nischalan Pillay (N)

Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.

Andreas Von Deimling (A)

Department of Neuropathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Stephan Beck (S)

Medical Genomics Research Group, University College London, UCL Cancer Institute, London, UK.

Adrienne M Flanagan (AM)

Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH